US Patent 10,016,415: Scope, Claim-Level Coverage, and U.S. Landscape
United States Patent 10,016,415 is directed to an aqueous nanoparticle composition defined by (i) polysorbate 20 as a stabilizing/excipient component, (ii) a particle population defined by a narrow Dv50 range of 350 nm to 175 nm (as stated in the claims), and (iii) a fixed particle-to-polysorbate 20 ratio of 17:1. Dependent claims narrow the formulation to sodium citrate (chelating agent), sodium chloride (tonicity agent), and specific weight percentages.
The enforceable scope is primarily shaped by three claim pillars: (1) particle size distribution (Dv50) range, (2) a strict 17:1 ratio to polysorbate 20, and (3) compositional inclusion of chelator/tonicity/buffer plus a defined particle compound.
What is the core claim scope (independent claims 1, 2, 6, 8)?
Claim 1 scope: particles + polysorbate 20 with Dv50 and 17:1
Claim 1 covers a composition consisting of:
- Polysorbate 20
- A population of particles defined by a chemical formula (not reproduced in the prompt text)
- A particle size criterion: Dv50 between about 350 nm and about 175 nm (light scattering determination)
- A ratio: particles to polysorbate 20 = 17:1
Claim 1 is a minimal excipient scaffold. It does not require chelators, tonicity agents, or buffers. That makes it the broadest structural hook if the same particle species and size/ratio are met.
Practical enforceability note: “consisting of” limits the formulation to the recited items plus anything necessarily present for size measurement, but it is typically read to exclude additional deliberate excipients.
Claim 2 scope: adds chelator, tonicity, and buffer
Claim 2 adds to claim 1:
- A chelating agent
- A tonicity agent
- An aqueous buffer
- Same particle population definition
- Same Dv50 range and same 17:1 particles-to-polysorbate 20 ratio
Claim 2 increases coverage of real-world product formulations because most aqueous nanoparticle dispersions use stabilizers plus buffering and ionic control. It also tees up dependent claims 3 and 4 that select specific exemplars.
Claim 6 scope: fixes quantitative formulation
Claim 6 is a composition consisting of:
- About 26 weight percent of a particle compound of a stated formula
- 1.53 weight percent polysorbate 20
- 0.76 weight percent sodium citrate
- 0.31 weight percent sodium chloride
- an aqueous buffer
- Same particle size criterion: particles provided as a population with Dv50 350 nm to 175 nm (light scattering)
This claim is narrower than claims 1 and 2 because it locks in specific component types (sodium citrate, sodium chloride) and specific concentrations (1.53% polysorbate 20, 0.76% citrate, 0.31% NaCl), while still using “about,” which typically adds tolerance around the weight percentages.
Claim 8 scope: aqueous dispersion
Claim 8 (as written in the prompt, “claim 2, wherein the composition is an aqueous dispersion”) confirms the physical form as aqueous dispersion, tying back to the presence of buffer in claim 2.
How do dependent claims narrow the composition (3, 4, 5, 7)?
Claim 3: sodium citrate as chelating agent
Claim 3 limits claim 2 such that:
- chelating agent = sodium citrate
This is a conventional pairing with nanoparticle dispersions and is a strong hook for products that use citrate to manage ionic strength and metal-catalyzed degradation pathways.
Claim 4: sodium chloride as tonicity agent
Claim 4 limits claim 2 such that:
- tonicity agent = sodium chloride
This is a direct “tonicity matching” formulation element. It matters because some products instead use sugars (trehalose, mannitol) or buffered saline without explicit NaCl selection.
Claim 5: combines citrate + NaCl with polysorbate 20 + buffer + particles
Claim 5 is the fully specified embodiment consistent with claims 3 and 4:
- polysorbate 20
- sodium citrate
- sodium chloride
- aqueous buffer
- particle population with Dv50 350 nm to 175 nm
- particles-to-polysorbate 20 ratio 17:1
This is the formulation-level claim that aligns with many clinical liquid or reconstituted aqueous products.
Claim 7: preserves the 17:1 ratio
Claim 7 states claim 2’s composition includes the 17:1 particles-to-polysorbate 20 ratio.
Because claim 2 already includes the ratio in the prompt text, claim 7 mostly functions as an explicit restatement of a critical limitation to reduce validity arguments based on potential claim parsing disputes. In practice, it reinforces the “ratio must be met” argument.
What are the claim-limiting technical parameters that drive infringement analysis?
1) Particle size criterion: Dv50 range
All key claims impose:
- Dv50 between about 350 nm and about 175 nm
- Determined by light scattering techniques
Even with “about,” the size criterion is the most common point of differentiation for design-around:
- If a competitor shifts the Dv50 materially above or below the stated range, they can avoid literal infringement if measurement confirms outside the “about” tolerance.
- If competitors use different measurement modalities, the claim language still anchors to “light scattering techniques,” which are widely used (DLS, laser diffraction with appropriate reporting). The litigation focus typically becomes whether the competitor’s test method produces a Dv50 that meets the claim range.
2) Fixed formulation ratio: particles to polysorbate 20 = 17:1
The ratio “17:1” is a quantitative limiter:
- If a product changes polysorbate concentration to adjust micellar coverage or stability, it can disrupt the required ratio.
- If the competitor adds additional surfactant other than polysorbate 20, “consisting of” language can create an exclusionary effect.
3) Composition constitution: “consisting of”
Claims 1, 5, and 6 use “A composition consisting of …” which generally constrains the formulation to the named components (and any components implied as part of the defined particle population).
- Design-around often targets the ability to argue the formulation includes additional excipients beyond those recited. Whether that is legally viable depends on the claim construction and file history.
4) Particle chemical identity
The claims require a particle population “of the formula” (not provided in the prompt text). This means infringement is not only about size and excipients; it depends on whether the particle compound is the claimed species (or a literal equivalent under doctrine of equivalents depending on jurisdiction and claim construction).
Where is the patent likely strongest vs. weakest (claim-by-claim enforcement posture)?
Strongest hooks
- Claim 1: anchors on (i) polysorbate 20, (ii) the particle species, (iii) Dv50, and (iv) the 17:1 ratio with no need to prove citrate/NaCl/buffer.
- Claim 5: anchors on a realistic aqueous formulation (polysorbate 20 + citrate + NaCl + buffer) plus Dv50 and ratio.
- Claim 6: anchors on fixed quantitative concentrations and specific salts.
Likely weakest hooks
- Any competitor that can credibly produce a particle dispersion with Dv50 outside the range or with a non-17:1 ratio can weaken literal infringement for all claims that require those parameters.
- If “consisting of” is strictly enforced, added stabilizers (even if functionally similar) may avoid literal coverage for claim subsets that exclude them.
Design-around map (what changes a product can make without crossing into the same claim elements)?
Primary design-around levers
- Dv50 shift: move the measurable Dv50 to outside 350 nm to 175 nm under a light scattering method.
- Ratio shift: change polysorbate 20 level such that the particles-to-polysorbate 20 ratio is not 17:1.
- Component selection: replace sodium citrate or sodium chloride with alternate chelators or tonicity agents to avoid claims 3-5-6.
- Constitutional drafting: add excipients that would defeat “consisting of” if the court construes it strictly (this lever depends heavily on claim construction and prosecution record).
Secondary levers
- Physical form: if a product is not an aqueous dispersion (claim 8 tethered to claim 2), that can affect narrower claims that insist on aqueous dispersion. Claims 1 and 5 still focus on composition constitution, so “non-aqueous” may not fully avoid if claim language is satisfied in the relevant parts.
Claim-to-product matching checklist (infringement-oriented)
For any candidate generic or follow-on product, the key evidence set is:
| Element |
What the claim requires |
Evidence typically used |
| Particle identity |
“population of particles of the formula” |
composition characterization, synthesis records, analytical confirmation |
| Particle size |
Dv50 between about 350 nm and 175 nm by light scattering |
DLS/laser diffraction method report; batch-level data |
| Ratio |
17:1 particles to polysorbate 20 |
formulation recipe; gravimetric/assay of polysorbate and solids |
| Polysorbate inclusion |
polysorbate 20 present |
excipient label and assay |
| Chelator/tonicity |
sodium citrate and sodium chloride (claims 3-5-6) |
formulation and assay |
| Buffer |
aqueous buffer required in claims 2/5/6 |
excipient composition analysis |
| Concentrations |
in claim 6: ~26% particle compound, 1.53% polysorbate 20, 0.76% sodium citrate, 0.31% NaCl |
formulation characterization, batch QC |
U.S. patent landscape: how to frame risk around US 10,016,415
1) Landscape structure around “nanoparticle + polysorbate + size range”
Even without the full asserted particle compound name in the prompt, the claim architecture signals a landscape where:
- Multiple patents may exist on the same particle compound with different stabilizers.
- Separate patents commonly cover buffer systems, tonicity agents, and surfactant selection in aqueous nanoparticle dispersions.
- Size control using formulation and processing is often the differentiator in follow-on IP.
In practical freedom-to-operate (FTO) terms, the risk driver is whether nearby patents cover:
- the same particle species formulated in aqueous media with polysorbate 20
- the same Dv50 window
- the same fixed ratio of particles to polysorbate 20
- the same salts (citrate and NaCl) in combination
2) Likely role of neighboring patents
For a patent set like this, the nearby U.S. landscape typically splits into:
- Patents on the particle itself (synthetic/particle composition)
- Patents on formulation (polysorbate selection, buffer, salts)
- Patents on process for achieving Dv50 (milling, precipitation, re-dispersion)
- Patents on measurement or stabilization of dispersions
US 10,016,415, as drafted, sits squarely in formulation-space claim scope with a tight particle-size constraint.
What does this mean for generics and product life-cycle strategy in the U.S.?
A. If a product matches all three pillars, risk is high
When a follow-on dispersion:
- matches the particle compound, and
- hits Dv50 within the stated window by light scattering, and
- uses polysorbate 20 at a 17:1 particles-to-polysorbate ratio,
the claims 1 and 2 are directly implicated, and claims 5 and 6 can be added depending on whether citrate and NaCl are used and at what concentrations.
B. If only size or ratio changes, risk becomes a litigation proof problem
If the competitor changes:
- Dv50 or
- the 17:1 ratio
then infringement turns on how “about” and light-scattering reporting are treated, and on batch reproducibility.
C. If salts change, claim-coverage narrows
Replacing citrate or NaCl can reduce exposure to claims 3-6, but claim 1 may remain in play if polysorbate 20 and the particle/size/ratio constraints are met.
Key Takeaways
- US 10,016,415 is a formulation IP patent anchored on an aqueous nanoparticle dispersion with polysorbate 20, a particle population defined by chemical formula, and two quantitative constraints: Dv50 between about 350 nm and about 175 nm and particles-to-polysorbate 20 ratio of 17:1.
- Claim 1 is broad because it does not require citrate or NaCl; claim 2 adds chelator/tonicity/buffer; claims 5 and 6 lock to sodium citrate and sodium chloride, with claim 6 additionally fixing concentrations.
- The enforcement center of gravity is the combination of particle identity + Dv50 window + 17:1 ratio, with “consisting of” language creating potential exclusion of additional excipients.
- U.S. landscape risk is highest for competitors whose formulations match the same surfactant (polysorbate 20) and size/ratio targets, even if they adjust citrate/NaCl selections.
- The most effective design-around levers are shifting Dv50 and breaking the 17:1 ratio; changing citrate/NaCl chiefly addresses dependent claim coverage.
FAQs
1) Which claim is most important for broad coverage?
Claim 1 is the broadest because it requires only polysorbate 20 plus the defined particle population with the Dv50 range and 17:1 ratio, without mandatory chelator/tonicity/buffer.
2) What are the two numerical limitations that most often decide literal infringement?
The Dv50 size range (350 nm to 175 nm, “about”) and the particles-to-polysorbate 20 ratio (17:1).
3) Do citrate and sodium chloride matter for all claims?
No. Claims 3-6 require sodium citrate and/or sodium chloride, but claim 1 does not.
4) Why does “consisting of” matter strategically?
It narrows the allowable formulation components to those recited, which can create an exclusionary argument if a competitor includes additional deliberate excipients.
5) What formulation changes best reduce exposure?
Changing particle size (Dv50) and/or the 17:1 particles-to-polysorbate 20 ratio offers the strongest first-pass separation; salt substitution mainly reduces coverage for the dependent claims that require citrate and NaCl.
References
[1] U.S. Patent No. 10,016,415 (claims as provided in the prompt).
